FDA gives priority review status to Novartis’ breast cancer drug
Pharma giant Novartis has secured the US Food and Drug Administration (FDA) Priority Review for its advanced breast cancer drug ribociclib (LEE011).
The drug is intended to be used in combination with letrozole as a first-line treatment of postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
